Life Sciences Archive » October, 2017

Life Sciences - October, 2017

366 articles

• Investor Tells Of Cash-Out Woes In Trial Of Ex-Katten Atty
• Ex-Biopharma Exec Enjoined From Sharing Trade Secrets
• Walgreens Hit With Suit Over Prescription That Killed Child
• Valeant Pays $13M To End Diabetes Drug Royalty Claims
• 'Poorly Drafted' Patent Deals Can't End Janssen Suit: Judge
• Feds Seek 20 Years For Ex-ArthroCare CEO For $750M Fraud
• 5 More Companies Launch IPOs Seeking To Raise $692M
• Drugmakers Want Chicago's Opioid Suit Paused Pending MDL
• Insys Founder Resigns From Board After Opioid Charges
• Walgreens, CVS, Others Exit Lidoderm Antitrust MDL
• Deals Rumor Mill: Petrobras, SenseTime, Staples
• Without Motive, Murder Hard To Prove In Meningitis Trials
• Full Fed Circ. Asked To Review Ensnarement In $200M IP Suit
• FDA Lets 8 EU Regulators Conduct Its Drug Inspections
• J&J Calls Witness Tampering Accusation 'Overblown'
• State AGs Triple Size Of Generic Price-Fixing Litigation
• J&J Unit Hit With Trimmed FCA Suit Over Hip Implants
• NJ Sues Purdue Pharma Over Opioid Marketing
• Judging A Book: McConnell Reviews 'Unequal'
• No Basis For Personal Jurisdiction In MDL Direct Filing
• Alere Infringed Blood Analysis Patents, Suit Says
• Japan's Kirin Readies $780M Exit From Amgen Joint Venture
• Eye Drug Co. Can Relocate Shareholder Suits To Mass.
• J&J Toxicologist Defends Brand's Talc In Mesothelioma Trial
• Retrophin Privilege Fray Irks Judge At Ex-Katten Atty's Trial
• Union Sues J&J Over Alleged Remicade Monopoly Plot
• Health Care Fraudster Gets 2.5 Years For Role In $175M Plot
• Drug Developer Must Face Suboxone Product-Hopping Claims
• Par Pharma Suit Tests FDA's Drug Pricing Pushback
• Mylan Scores Costs After Win In Blood-Thinner IP Row
• Surgeon Picks Bone With J&J's DePuy Over Spinal Device
• Montel Williams Says Pot Cos. Used His Name In 'Fake News'
• PTAB Reverses Course, Institutes Review Of Herceptin Patent
• NPR Station Can Get Meningitis Juror Names, But Must Wait
• Novartis To Pick Up French Cancer Drug Co. In $3.9B Deal
• Making Pro Bono Work
• Being There: Preparing Witnesses For Depositions
• Post-Grant Proceedings As A Freedom-To-Operate Tool
• 7 Firms To Guide IPOs Exceeding $1.8B Led By Cement Giant
• FCA Decision Tracker: Continued Interpretations Of Escobar
• High Court Urged To Review State Immunity In UMass IP Row
• Merck Can't Escape Fosamax MDL, Patients Tell High Court
• Amgen 'Completely Ignoring' Biosimilar Law, Genentech Says
• Stanford's $8M Clinical Worker OT Deal Stalls On PAGA Cut
• Mylan Gets Teva's Copaxone Patent Invalidated By UK Court
• Fired GNC Manager Wins $250K Verdict In Age Bias Suit
• Bristol-Myers Dodges Revival Of Abilify FCA Suit At 6th Circ.
• Vitamin Maker Gets Trim Of 'Made In USA' Class Action
• Making Pro Bono Work: The Sidley-Exelon Partnership
• Despite Good Intentions, IPR Clashes With Hatch-Waxman
• Rejecting FTC Drug-Level Standard On Dietary Supplements
• Recipe For Legal Project Management: Look To BBQ Champs
• J&J Talc Caused Woman's Mesothelioma, Expert Tells Jury
• Eager To Run, Fla. Medical Marijuana Industry Crawls Forward
• Parent Company Escapes Suboxone Product-Hop Suit
• Medco Dodges 4th Version Of Drug Fraud FCA Suit
• Ropes & Gray DQ'd In Guardant Health's False Ad Suit
• Fed. Circ. Affirms Obviousness Of Merck Antibiotic Patent
• Bayer's Financing Needs Shift As Monsanto Price Falls $2.5B
• GSK, Teva See Bigger Issues Than Cash In $235M Award Fight
• Insurer Says Tissue Bank Not Covered For Nitrogen Death
• Trump Declares Opioid Emergency, Critics Call For Funding
• Stryker's 'Intrusive' Hip Implant Patient Survey Rejected
• Deals Rumor Mill: CVS, Weinstein Co., Evoqua Water Tech
• Gilead's Lucrative Hep C Patents Face PTAB Assault
• Defeated AndroGel User Must Pay Own Bills, AbbVie Says
• With New Scrutiny, Life Sci Startups Become Risky Targets
• Insys Founder Charged With Racketeering In Opioid Scheme
• Sanofi Says Mylan Infringing 18 Insulin Patents
• Insurer Seeks To Recoup Costs Of Implant Co. Suit At 9th Circ.
• Tax Court Flouted Regs In Medtronic Case, IRS Tells 8th Circ.
• Xytex Settles Claims Over Poorly Screened Sperm Donor
• Making Pro Bono Work: Can You Practice In Your State?
• 9th Circ. Endangers Mass Action Removal Under CAFA
• Representing Women At The Intersection Of Law And Finance
• Retrophin Ex-Chairman Says Ex-Katten Atty Not Independent
• Purdue Faces US Probe Over OxyContin Marketing
• Unilife Ch. 11 Plan Gets Interim OK, Despite Gaps
• FDA Defends Cigar Regs, Points To Consumer Misperceptions
• Supplement Cos., Execs Indicted Over Hidden Stimulants
• RI Doc Admits To Health Fraud, Opioid Kickback Scheme
• What To Watch For As US Reboots India Trade Engagement
• Second Pharmacist Convicted In Meningitis Outbreak Trial
• Deals Rumor Mill: Pfizer, Deutsche AM, Learning Care Group
• Teva, Mylan Win Toss Of Allergan Ulcer Drug Patent Suit
• Recent Disasters Highlight Drug Shortage Problem
• Belgian Biotech Ablynx Raises $200M In Upsized IPO
• Compounder Can't Duck Drug Marketing Suit, Allergan Says
• Making Pro Bono Work: Building Sponsorship Relationships
• PTAB Won't Review Japanese Co.'s Antibody Tech Patents
• House Bill Would Raise Stakes Of Congressional Inquiries
• What I Learned In My 1st Year: Be A Sponge
• Pomerantz Gets Lead Role As Juno Investor Class Certified
• J&J Talc User's Body Had Asbestos In It, Jury Hears
• Ex-Katten Atty Seeks To Chase Shkreli's Specter From Trial
• Drinker Biddle Attys Deny Pressuring Doc In Hip Implant Trial
• Eli Lilly Considers Sale Or IPO Of Animal Health Business
• Pharma Cos., States Battle Over Opioid Litigation Transfer
• Jury Hints At Racketeering Conviction In Meningitis Case
• Pharma Insider Trading Suspects Deny Using Nonpublic Info
• FDA Warning Wire: NYC's Most Expensive Restaurant
• Stanford, ThermoLife Can't Trim $1.3M Atty Fees In IP Suit
• Making Pro Bono Work: Beyond The Hurdles
• 2nd Circ. Won't Revive Mirena Injury MDL Against Bayer
• Amgen, Hospira Challenge $70M Biosimilar Judgment
• Ensnarement 101: Anatomy Of An Uncommon Patent Defense
• Stacking The Deck Against Opioid Plaintiffs
• J&J Wins Battle Against $417M Talc Award, But War Not Over
• Ex-Katten Atty Was Shkreli's Right-Hand Man, Jury Hears
• Allergan Patent Deal Is No Sham, Tribe Tells PTAB
• 'White Hats' Face Red Tape As Data Gets Deadly
• Patients Ask 7th Circ. To Revive Pfizer Testosterone Suits
• Justice Dept. Wants To Pause Pharma Insider Trading Row
• GE Wants Maine Law To Govern Asbestos Exposure Claims
• Doctors' Counsel Nab $27M In Sanofi Vaccine Antitrust Row
• TPG Picks Up Medical Device Maker Exactech In $625M Deal
• Judging A Book: Pryor Reviews 'Scalia Speaks'
• Lewis Brisbois Nabs Product Liability Trial Atty In San Diego
• 15 Minutes With Teva Pharmaceuticals' General Counsel
• The Inside Counsel Revolution
• Stockpiling Biologics Under Hatch-Waxman Protection
• J&J Wins Toss Of $417M Talc Cancer Verdict In Calif.
• Abbott Can't Escape Failure-To-Warn Claims In Depakote Suit
• Boehringer Sues Drugmakers To Block Generic Gilotrif Plans
• If J&J Talc Had Asbestos, It Could Cause Cancer, Expert Says
• Opioid Litigation Roundup: An Overview Of Major Cases
• Investor Sues McKesson Over Opioid Oversight Fines
• Dental Tech Co. Wins $6.8M In Trade Secrets Suit
• Sony-Fujifilm Feud Lands Among New ITC Probes
• Gilead Gets Hep C Drug Patent Suit Shipped To Calif.
• Ex-Katten Atty Betrayed Client, Feds Say As Trial Starts
• Meningitis Outbreak Murder Trial Sent To Jury
• Teva's Generic Bowel Drug Infringes Patent, Allergan Says
• 7 Firms To Guide IPOs Topping $2.1B As October Heats Up
• Doctors Fight Allergan's Attempt To Defeat Botox Pricing Suit
• RI Atty Can't Ditch Texas Suit Over Hernia Mesh Litigation
• Miss. High Court Tosses $2M Risperdal Verdict Against J&J
• How District Courts Treat Patent Eligibility In Life Sciences
• Fed. Circ. Won't Toss Mylan's Appeal Of Epilepsy Drug Patent
• Xarelto Users Taking First Two Trial Losses To 5th Circ.
• Fed. Circ. Won't Rethink Lymphoma, Myeloma Drug IP Revival
• Drinker Biddle DQ'd In Pa. Pharma Partnership Fight
• Taxation With Representation: Skadden, Sullivan, Wachtell
• How Arbitrators Maintain Proportionality In Discovery
• Ex-Pharmacist In NECC Meningitis Case Puts Blame On Boss
• Benefits Co. Rips Injunction Bid In $1.5B Antitrust Suit
• NJ Wants To Yank Doc's License For Overprescribing Opioids
• Ex-Katten Atty's Jury Won't Hear Of Shkreli Acquittal
• PTAB Issues 1st AIA Deadline Extension To Address Aqua
• Fed. Circ. Rules Judge Wrongly Axed Merck NuvaRing Patent
• 11th Circ. Upholds $27M Boston Scientific Pelvic Mesh Loss
• J&J's Talc Bore Harmful Asbestos, Calif. Retrial Jury Told
• Ex-Lead PTAB Judge Heads To Haug Partners
• Deals Rumor Mill: Unilever, easyJet, Sinochem
• AbbVie Must Face Suit Over Failed Shire Deal In Ill. Court
• Cancer Drug Maker Ends Stock Drop Action, For Now
• Still Difficult For Patent Holder To Use Equivalents Theory
• The Law Firm CFO's Role In The Strategic Planning Process
• Cos. Pursued By FTC Show How Not To Sell Health Products
• Judge Hesitant To Rubber-Stamp Aegerion's $36M Fraud Deal
• Bayer Seeks To End One-A-Day Labeling Class Action
• Generic-Drug Maker Faces Sanctions As Adderall Trial Closes
• NPR Station Wants Names, Addresses Of Meningitis Jurors
• Aurobindo Loses Fee Bid After Beating Mucinex Patent Suit
• Bayer, Others Sued Over Radioactive Waste Near Niagara Falls
• 3rd Circ. Revives Eyedrop Users' Action Over Dosage Size
• Mintz Levin Snags Ex-Foley IP Partner In San Diego
• Chicago Seeks Janssen Employees' Info In Opioid Suit
• Law Firms Must Transition To An Industry Sector Approach
• EU Accepts Becton Dickinson's Fixes For $24B Bard Buy
• Latham Snags Ex-Fish & Richardson Patent Atty In DC
• Sham Affidavits In Medical Product Liability: Part 2
• J&J Wins Mo. Appeal Of $72M Talc Cancer Verdict
• Shkreli Acquittal Inadmissible At Trial, Gov't Argues
• Restasis Ruling Could Be Bad Sign For Tribal Patent Pacts
• Tampering Flap Puts J&J Trial Attys Under Ethics Microscope​
• Sens. Scrutinize Murky Drug Pricing, Rebate Deals
• Boss Pushed Pharmacist To Step Up Testing Before Outbreak
• Pay Equity PAGA Suit Alleges Gender Bias At Calif. Co.
• Impax, Amneal Ink Deal To Become $1.75B Generics Giant
• FDA Warning Wire: Multiple Issues At Dialysis Co.
• Merck Gave Doctors Hawaii Trip Kickbacks, 9th Circ. Told
• Bio-Rad Asks 9th Circ. To Undo $8M Verdict For Ex-GC
• Reckitt Benckiser Dodges States' Suboxone Case
• J&J Asbestos Trial A New Front In Talc Litigation
• Judging A Book: Kozinski Reviews 'The Judge'
• Liberty Needn't Cover Client's $3M Expenses In SEC Probe
• Sen. Wants Repeal Of Opioid Law That Sunk Drug Czar Pick
• Tribal Immunity May Not Be Wonder Drug For Allergan
• Anti-Inversion Rule Down, But Not Out, With Texas Ruling
• Rep. Who Cut DEA Powers Out As Trump's Drug Czar Pick
• Sham Affidavits In Medical Product Liability: Part 1
• End-Payors, Direct Purchasers Get Cert. In Solodyn MDL
• Neutrogena Buyers Seek Class Cert. In Sunscreen Label Row
• Ex-Katten Atty Loses Bid To Nix Shkreli Conspiracy Charge
• Prevagen Memory Product Maker Fights Cert. In Ad Suit
• Gov't Scientists Tell Of Rare Outbreak As Trial Nears End
• Mo. High Court Pauses J&J Talc Cancer Trial Over Venue Row
• FDA Finding Doesn't Absolve Forest Labs, Parents Say
• Judge Hacks Away At Allergan's Restasis Patents
• Fresenius Can't Duck FCA Claims Over Hepatitis B Tests
• Janssen Defends Role As Sole Patent Owner In Remicade Suit
• PharMerica Says FCA Whistleblowers Got Info Secondhand
• Counsel In J&J 'Natural' Labeling Suit Seek $2.25M Fees
• Evolution Of A Crisis: Opioid Claims Pick Up Speed
• New Post-Recession Metrics For BigLaw Partner Success
• Understanding FDA Guidance On Connected Medical Devices
• Allergan, Generic Cos. Debate If Tribal Patent Deal Is A 'Sham'
• Actavis Generic Infringed Weight Loss Pill Patent, Judge Says
• Eliquis MDL Sees 24 Suits Trimmed Due To Forum Rule
• Fla. Denied Bid To Remove Judge In Medical Pot License Suit
• 9th Circ. Judge Balks At Blue Shield Customers' Cert. Bid
• Pfizer Takes $8.3M Interest Case Against US To 2nd Circ.
• J&J Loses Remand Fight In NJ Talc MDL
• Susman, Entwistle To Lead Valeant Insider Trading Suit
• Insulet Hit With Derivative Suit Over Lack Of Disclosure
• FDA Shuts Down Calif. Dietary Supplement Maker
• PE-Backed Biotech OptiNose Raises $120M In Upsized IPO
• UK Anti-Competitive Probe Targets South African Drugmaker
• Time To Lift Student Loan Counseling Restrictions
• Pa. Health Dept. Asks Court To Uproot Medical Pot Permit Suit
• Generic-Drug Lobby Asks 4th Circ. To Halt Md. Pricing Law
• Health Hires: Boston Scientific, Mintz Levin
• Allergan, Pfizer Unit Reach Deal Over Generic Dry-Eye Drug
• J&J Cites Jury Misconduct In Bid To Nix $417M Talc Verdict
• What To Expect As BigLaw Vet Eric Hargan Runs HHS
• 3 Places The Allergan Tribal Deal May Face Pushback
• Online Auto Seller Cargurus Leads 3 IPOs Totaling $227M
• Ex-ArthroCare CEO Can't Undo $750M Fraud Conviction
• Dimension Investor Sues To Block $151M Ultragenyx Merger
• 7th Circ. Won't Revive Payors' Depakote Suit Against Abbott
• Mass. Ruling Doesn't End NJ Eyedrops Case, 3rd Circ. Told
• CVC Capital, Tethys Close To Acquiring Sebia Majority Stake
• Amgen Defends $70M Biosimilar Verdict Against Hospira
• USPTO Rips 'Vitriolic' Attack On New Atty Fees Rule
• Pepper Hamilton Lands Ex-Saul Ewing Life Sciences Leader
• Microsoft Ruling Dooms Cymbalta Labeling Suit: 9th Circ.
• 1st Circ. Won't Rethink Ending Sarepta Securities Suit
• Trio Of Pharma Cos. Fight Post-Trial Bids In $1B Patent Row
• BPCIA At Fed. Circ.: Awaiting Guidance On Patent Dance
• Gorilla Glue Case Shows Cannabis IP Is Not Sticking
• 'Dr. Jekyll' Pharma Insider Trading Suspect Released Again
• Ex-Grant & Eisenhofer's Atty Looks To End $7M Fee Fight
• Philips, DOJ Reach Deal Over Defibrillator Missteps
• J&J Unit Says Wrong Venue Merits Toss Of $12M Mesh Award
• NuVasive Says Exec Breached Contract In Move To Alphatec
• Why You Should Consider Hyperlinking Your Next Brief
• Deals Rumor Mill: Novartis, Air Berlin, BMW
• Xarelto Internal Bleeding Suit Nixed As Time-Barred
• FDA Expert Testifies Of Unparalleled Contamination At NECC
• Cancer Center Settles Genetic Testing Licensing Breach Suit
• Buchanan Ingersoll Hires Kirkland Pharmaceuticals Litigator
• Tribe Bought Patents With Immunity Promise, Allergan Says
• Hi-Tech To Pay $40M In Sanctions In FTC Labeling Suit
• How Bristol-Myers Squibb May Transform Class Actions
• Trump Taps Greenberg Traurig Vet As Acting HHS Chief
• Ex-Katten Muchin Atty, Prosecutors Submit Revised Juror Q's
• Plaintiffs Can't Drop Cases Before Depakote Trial: Judge
• Supplement Co. Defends Tactics After Atty's Site Attacked
• Deals Rumor Mill: CeramTec, Atlantia, Helix Energy
• 3 Meningitis Pharmacy Workers Must Face FDA Fraud Claims
• FDA Warning Wire: Bush's Baked Beans, Univ. Of Michigan
• Asian-Americans Facing Challenges In The Legal Industry
• Mass. AG Runs Point As Top Trump Critic
• Pharma Rights Transfer Sinks Tax Deficiency, 3rd Circ. Told
• Allergan Ordered To Prove Tribe Patent Deal Isn't A 'Sham'
• Mistrial Declared In Case Alleging Asbestos In J&J Talcum
• Good And Bad News For Massachusetts Life Sci, Health Cos.
• What Duties Do Lead Lawyers Owe MDL Plaintiffs?
• Asbestos In J&J's Talc Caused Woman's Illness, Jury Told
• Forest Labs To Pay $4M To End Gender Bias Suit
• Amgen Sues Genentech To Shield Avastin Biosimilar
• MDL May Be On The Horizon In Opioid Litigation
• Judge Unlikely To Dismiss Ex-Katten Atty Conspiracy Count
• Pharmacist In Meningitis Trial Ignored Drug Recipe, Jury Told
• Generic Cos. Say Mass. Ruling Foils 3rd Circ. Eye Drop Case
• McCaskill Drafts Bill To Block Tribal Immunity In Patent Review
• A BigLaw Ladies' Guide To Becoming A 1st-Chair Trial Lawyer
• Collegium Infringing OxyContin Patents, Purdue Says
• Texas Justices Tackle 11th Circ.'s Discovery Rule Question
• Farmers Fight Syngenta Bid To Speed $218M Verdict Appeal
• Biotech Firm Can Arbitrate Patent Row At AAA, Chancery Says
• Strategies For Protecting Biotechnology In Brazil And China
• $60M Merck Pay-For-Delay Deal, $20M Atty Fees Approved
• Womble Carlyle Adds McCarter & English Patent Pros
• Medline Says CR Bard Copied Innovative Surgery Kit
• Pa. Gov. To Sign 'Right To Try' Unapproved Drugs Bill
• Attys Argue For 1/3 Slice Of $15M Asacol Deal Pie As Fees
• Foot Care Co. Says Rival Exploited Its IP In Online Sales
• Eli Lilly Beats Challenge To Cancer Treatment Patent
• Gov't Backs Strict FCA First-To-File Bar In Allergan Case
• Feds Re-Up Bid To Ban 5 Experts In Ex-Katten Atty's Trial
• Meningitis Pharmacist Brushed Off Concerns, Colleague Says
• NJ Sues Insys Over Opioid Drug Push, Calls Conduct 'Evil'
• Jilted Pa. Medical Marijuana Bidder Drops License Challenge
• IRS Can't Fight Facts In Transfer Pricing Suit, Medtronic Says
• 2nd Bellwether Jury Says AbbVie Owes AndroGel User $140M
• Fed. Circ. Erases Amgen Win Over Sanofi Cholesterol Drug
• Novartis, Genentech Again Beat Xolair Kickback Suit
• PharMerica Must Face State FCA Claims, Whistleblowers Say
• Insys To Pay $500K To End Mass. Opioid Marketing Claims
• Fed. Circ. Judge Recoils At Cesspool Remark In Axiron Suit
• J&J, DePuy Lose Bid To Pause FCA Ruling At 1st Circ.
• A New Strain Of Inequitable Conduct Litigation
• When Plaintiff Conduct Matters: Part 3
• 5 Tips To Ensure Proper Deposition Behavior
• Thoratec Investors' Heart Device Suit Revived By 9th Circ
• Atty's Tactic At USPTO Not Illegal, Judge Says
• End Payors Urge 4th Circ. To Revive Celebrex Antitrust Suit
• Calif. Appeals Court Revives Snoring Aid Class Action
• Consumers Sue J&J Unit Over Products' Hair Repair Claims
• Budd Larner Patent Litigator Joins Greenberg Traurig
• Greenberg Traurig Vet Gets Senate Nod For HHS Deputy
• Drug Co., Investors Win OK For $3.4M Stock Drop Deal
• Investor Seeks 'Phantom Pain' Device Co.'s Shareholder List
• Allergy Care Antitrust Case Headed Toward Trial
• AbbVie, Lilly Slam Discovery Bid In Testosterone MDL
• Feds Fight Ex-ArthroCare CEO's Bid To Nix Fraud Conviction
• Pa. Pharmacy To Pay $2.67M To Resolve FCA Allegations
• The Future Of Value-Based Care After Repeal And Replace
• When Plaintiff Conduct Matters: Part 2
• J&J Unit Fights To Save Remicade Patent At Fed. Circ.
• ACLU Sues FDA Over Access Restrictions To Abortion Pill
• Gilead To Take 9th Circ. Escobar Ruling To High Court
• 3rd-Party Release Constitutional, Millennium Labs Judge Says
• AbbVie's Marketing Of AndroGel 'Insidious,' Jury Told
• Novartis, Genentech Want 'Hopeless' Kickback Suit Tossed
• Allergan Tribal IP Transfer Sparks House Oversight Inquiry
• Fed. Circ. Looks At Early Statements In Neulasta Patent Row
• Keryx Seeks To Scrap Shareholder Stock-Drop Suit
• Billionaire Seeks To Pause Discovery In Supplement Co. Row
• Covidien Can't Stop Ethicon's Surgical Device Sales
• Chinese Lender Qudian Leads 2 IPO Launches Totaling $869M
• FDA Warning Wire: No Love For Playful Granola Labels
• Trump Admin Delays Penalties For Drug Price Overcharges
• Cephalon Slams Bid To Reinstate Pa. Opioid Marketing Suit
• Quest Tests Are Trade Secrets In Med Mal Suit, Pa. Court Says
• Vets Want DOD Docs About Radiation Exposure At Crash Site
• J&J, DePuy Ask 1st Circ. For Stay To Appeal FCA Ruling
• Hazy Outlook For Legislation Protecting Medical Cannabis
• Judging A Book: Tunheim Reviews 'Miles Lord'
• When Plaintiff Conduct Matters: Part 1
• Inversion Rule Defeat May Impair Regulatory Process
• Cher Alleges Biotech Co. Fraudulently Pushed Stock Sale
• Justices Let $3M Pelvic Mesh Verdict Against Ethicon Stand
• Justices Won't Review Calif. Co.'s Taxable Connection Case
• Ex-Katten Atty Fights To Keep 5 Experts In Shkreli Trial
• New Guidances Expand FDA Campaign On Drug Prices
• Novartis Not On Hook For Generic's Label, Calif. Justices Hear
• Valeant Launches $1B Private Bond To Restructure Debt
• PharMerica Looks To Duck Last Claims In Kickback Suit
• IP Attys Back Regeneron Over Inequitable Conduct Finding
• P&G Agrees To Pay Up To $30M To End Probiotic False Ad Suit
• Big Pharma Wants Opioid-Epidemic Class Claims Tossed
• Shire Hits Allergan With Antitrust Suit Over Dry Eye Drugs
• Feds Ask 1st Circ. To Revive Meningitis Outbreak Charges
• Technology Assisted Review Can Work For Small Cases
• GNC Hit With $20M Suit Over Supplement Co.'s Collapse
• Roche Ducks Cancer Drug Antitrust Suit
• Pharmacist In Meningitis Trial Says He Never Tried To Run
• Calif. City Can Block Tax-Delinquent Weed Shop, Panel Says
• Supreme Court Turns Down Trio Of Antitrust Appeals
• Pfizer Loses Bid To Stop Rebate Disclosures To Lawmakers
• Intuitive Surgical Can't Toss Investors' Robot Glitch Suit
• Law360 Sizes Up The Term To Come
• IRS Anti-Inversion Rule That Sank Pfizer Deal Struck Down